Biotech Values

[masterlongevity]

$SRPT not surprised by this. My bigger beef with him as a CEO is the not so subtle suggestions he gave to the market and patient community that the drug would be accepted for accelerated approval (last year). This was a false hope. He has consistently overpromised and underdelivered. Other issues I have with SRPT is the snail's pace at which they have gone from phase 2 to phase 3 (in fact trying to avid). instead of being prepared and getting the work done, they focused on taking a shortcut. Then the patient community blamed the FDA instead of the company as they should have. Another SRPT issue is the discordance with the biomarker data. The last big issue is that they have not provided comp use. I feel that other companies who think their drug is worthy of accelerated approval would have provided comp use until approval. It doesnt even appear they have tried. This drug may or may not work, but the mgmt team has completely bumbled it.